Protagonist Therapeutics, Inc Investor Event Transcript, Nov 17, 2026
Protagonist Therapeutics, Inc (PTGX)
Protagonist's CEO said J&J reported more than 20,000 prescriptions for Icotide, and that J&J guided toward breaking out its sales as a line item sometime in 2027. He also said over half a billion of milestones are pending. A decision on a second indication for the oral candidate is planned for the second half of next year, assuming enrollment proceeds at a decent pace. AI summary
Conference Transcript - PTGX 2026-11-17
Roger Song, Analyst — Jefferies
All right. Welcome, everyone, to Jeffrey's 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst covering Smica Biotech in the U.S. It is my pleasure to have the five-side chat with our next company, Protagonist Therapeutics, and we have the CEO, Dinesh Patel. Welcome, Dinesh.
Dinesh V. Patel, CEO
Always a pleasure to be here and to have a conversation with you, Roger.
Roger Song, Analyst — Jefferies
Excellent. All right, why not you just start with the brief overview of the protagonist, and then we're in a very enviable position right now, so give us a minute or two.
Dinesh V. Patel, CEO
Yeah, I mean, it has been a long journey, but finally we have arrived at a very good place, a very unique place at one end. It can be, uh, Kind of a company with two approved drugs, so we have entered into the quote-unquote commercial space, but without hiring a single Salesforce person, and that is by virtue of the two amazing partnerships that we did, you know, the right kind of partnership at the right time, one with J&J, the other with Takeda, and now, of course, the benefit of all that is you are validated. You and the team have this amazing satisfaction at the core level of having contributed to drugs that will make a difference in the life of patients, and you also get a very steady stream of revenue, which then in turn allows you to fund your own R&D engine without bad news for the bankers going out and raising, trying to raise money. So, and on top of that, we believe the flow of money will be of such magnitude that from time to time we should also be able to do share buyback. So, it's like compressing a lot in a single company, but I think these are all positives and, you know, we believe this is just the beginning, the mastery that we have over the peptide technology. is gonna enable us to do wonderful things as is reflected by our very thriving R&D pipeline.
Roger Song, Analyst — Jefferies
Excellent. Okay, and then you as you said you have a two commercial product through two major pharma partner and then everyone very focused on the IcoType and then Memorial also launching a pretty kind of So for the Ecotype, you know, changes on the driver's seat, and then how much you can say about, you know, the revenue and then royalty, trending, and then when, you know, if you will break up, then maybe next year.
Dinesh V. Patel, CEO
Yeah, so, I mean, clearly, Icotec has gotten a very high level of visibility, and maybe rightfully so, as you know, it also got nominated as one of the best innovative medicines by Time magazine, which is very satisfying for the scientific souls. And commercially, I mean, if you just look at the qualitative statements from J&J executives, right, I mean, the launch is like almost at an unprecedented scale of more than 20,000 prescriptions already as reported by J&J during their earnings call. And also a very nice distribution of like, you know, 60% are systemic naive, but 20% are switching from orals, and this is for psoriasis, obviously, and the other 20% are switching from injectables. This is a great beginning. Now, in terms of, like, you know, the precision of revenues and all that, we will follow J&J's lead. We don't want to outrun them, and I believe during their earnings call, they guided towards breaking it down as a line item sometime in 2027. Okay.
Roger Song, Analyst — Jefferies
Yeah, got it. Before that, I'm going to keep using my estimate. Fair enough.
Dinesh V. Patel, CEO
And by the way, I mean, we do have a good chunk of over half a billion of milestones also that are pending. And in theory, we believe all of those could be achievable because the kind of... The development milestones are geared towards second and third indications, NDA filings and approval, and the sales milestones, we don't believe the highest hurdle is, like, you know, if it crosses over a 5 billion mark in a given year.
Roger Song, Analyst — Jefferies
Got it. Okay, great. And then, you know, obviously, they keep expanding the indication into PSA, which is saw the data at ACR, and then also the UC and the CD, which is also a big indication for IL-23. And then another thing in the field is definitely moving towards the oral peptide. You know, you're leading that, and then the J&J is also benefit from there. How do you think about, you know, we see recent deal related to the long-acting oral peptide. So one is how you think about that approach, you know, compared to based on what your expertise in this field. And two is, is protagonist having some capacity or the capability to do something like that, longer-acting oral peptide?
Dinesh V. Patel, CEO
Yeah, I think maybe I'll answer the second question first. It's like we certainly have the capability of designing longer-acting oral peptides. What is probably unclear is what is the true differentiation value that could be derived from, let's say, a once-daily oral pill versus a once-weekly. One speak weekly is kind of uncharted territory. So scientifically, we certainly can do that. And at Protagonist, at least, we derive a big differentiation between what is it that we can do versus what is it that we truly choose to do. And differentiation is key at any given time. So I'll leave it at that. Now, in terms of, you know, the other indications, as you well know, our 23 injectable antibodies, there is such an amazing precedence, right? So the three main antibodies, Stellara, Trump, FIAS, Skyrizi, they have found 100% success in all four indications, psoriasis, psoriatic arthritis, UC, and Crohn's. So we feel very confident about the outcome. Psoriasis, it's already approved. Psoriatic arthritis, the primary endpoints were met. The data was very impressive. If you look at the absolute ACR numbers, I mean, ours is an oral pill, but it matches the numbers of scyrezy and tromphaea. And then you see the Phase II data, I believe, was outstanding, 30% clinical remission. That's about as high as it gets, right? So, of course, logically, there is a lot of confidence in these future indications. And the other thing I will add is, like, I mean, if you listen to J&J, they are repeatedly saying that all this clinical development with ICO is enrolling at an unprecedented pace. UC is a good example, right? Just about 10-15 days ago on clinicaltrials.gov, it's reported that the enrollment is complete, which according to my back-of-the-envelope math, that is... 9 to 12 months ahead of schedule. So that's wonderful.
Roger Song, Analyst — Jefferies
Yeah, got it. And then just a quick follow-up on this long-acting, the L23. So given your partnership, it's a great partnership with J&J. Will this, whatever you do additional for the L23, will be mostly with J&J, or something you can do that independently, maybe sign a different partnership with J&J?
Dinesh V. Patel, CEO
Yeah, so as you know, and you know, you have been following us over several years now, so the J&J Partnerships, that was inked all the way back in 2017 when it was a preclinical program, and then it has continued till today, and until Icotide got fully secured going into phase three, the research component was still going on. So you can imagine the two companies have been doing cumulative research all the way back from 2017, and it all falls under the broad category of joint research, joint collaboration, joint ownership kind of thing. So we believe that, yeah, that is a good place to be at, whether with J&J or independently.
Roger Song, Analyst — Jefferies
Okay, awesome. All right. And then Mim Rilo, I think Tequila also said this is going to be a very important launch for them, maybe one of the three major products. By the way, J&J say the Echotide will be the largest pharmaceutical product. I have to emphasize that. I'm glad you are stating it rather than me. No, it's changing. Not me. I just repeat that. So we also look at the historical, all the sales, the big franchise for J&J, it's up to 15 to 20 billion revenue. So for MemRylo, Takeda also put a lot of the effort behind, and then how do you think about, because it is a rare disease compared to the psoriasis and the R23, how do you think about the long trajectory, not for you to comment on that, but just looking at the epidemiology, what's your expectation looking at the MemRylo?
Dinesh V. Patel, CEO
Yeah, I think there are a number of things that come into play, right? I mean, if you look at Memriro, it's a hepcidin functional mammatic, and it's the first of its kind. At the core level, polycythema, whereas a disease is about, you know, excessive erythrocytosis. These patients have high hematocrit. This is the first and only drug that precisely addresses just that, because if you look at the current treatment paradigm, it kind of doesn't discriminate between RBCs versus, let's say, plate sets or white blood cells, right? And what we found is that uncontrolled hematocrit is an issue that prevails in all kinds of patients, low risk, high risk, people with early disease on step, late stage disease, that sort of thing. So the utility should be throughout the spectrum, so to speak, which is huge. And, you know, as you know, the label has been incredibly clean. No cancer carcinogenicity issues, and if at all anything, it's a broad label, and this is the first time ever that a drug in the PV space has formally a symptom improvement component in the label, the fatigue thing. And of course, last but not least, we have been smart enough to kind of not commercialize it on our own, but join a very capable company like Takeda and let them do the job. So I think the stars are incredibly well aligned. And last but not least, NCCN, you know, they recently gave up the guideline of putting this Memorello in the Category 1, and both for low-risk and high-risk population. And so, yeah, I would like to believe we are off to a wonderful start, and we would leave it up to our pharma colleagues to, you know, report the things in a proper way from time to time. Now, coincidentally, as you know, J&J is having their investor day on December 8th, and Takeda is having their capital markets day on December 11th, Japan time.
Roger Song, Analyst — Jefferies
Okay, got it. We're going to stay tuned on that. Okay, so I have to say PV, Polysysimiavera, getting a lot of attention, a lot more attention than the past year, particularly before the memorabilia approval and the phase three data. So now we recently saw Merck and then Silent, the deal, one plus billion. So you definitely get some more activity in this field. How do you think about those kind of longer-acting, maybe a similar target, but it's more endogenous, and then I believe you have an oral hepatitis as well. Is that the answer for the future, the competitor, and then what's the feedback you're getting? Because I believe that's your fully owned, and then maybe... Correct, correct.
Dinesh V. Patel, CEO
So, you know, whether it is with Icotide, I mean, now there are quite a few oral R23s that are being developed, right, by other companies, Whether you look at Memrilo, there will be longer-acting injectables, that kind of thing. But in both instances, our drugs are significantly ahead of everyone else, so we are going to enjoy that solo time, being the only sole presence, that kind of thing. Memrilo, if you think about it, is at least four, if not five years ahead of everything and anything. And look, that is part of, it's just a natural outcome of success, And the natural progression is like, yes, there will be other drugs that will be created that may have one sort of claimed advantage or the other. Time will tell. But if you think about it, what we have done in Memrile is like we introduced Memrile as a once-weekly injectable, and it's a rare disease indication. It's self-administered. So we believe it is very convenient. And the next inflection point, according to us, and as you know, we are kind of... We've focused quite a bit on oral drugs, so to speak, right? So the second act over here is an oral hepcidin functional mammatic, and we believe that we'll have a very good appeal, very good differentiation. We don't see any overlap or conflict with Memorilo. Memorilo is already approved. Our oral candidate is still preclinical. It goes into clinic next year, that sort of thing. So I think things are well balanced and well laid out.
Roger Song, Analyst — Jefferies
Okay, great. Okay, so we have 10 more minutes. I do want to talk about your two major emerging pipelines based on your oral peptide platform. One is IL-17, and then the other one is the GGG. I just came back from the obesity week. Definitely want to talk about that. So for the L17, you reported very impressive, the healthy volunteer data, and then that triggered you to do a full-blown, those ranging study in the very heavy investment, so it speaks to your confidence. And then I think you said you will have some data or intro analysis next year, and then decide which direction the next step. So tell us about the mechanism, and then what exactly are you going to see mid-year next year?
Dinesh V. Patel, CEO
Yeah, no, look, I think that's a great topic, and in a way, we encourage people saying, look, I mean, I quote, I have been an amazing success. Memrilo is also going to follow a similar path. But now, as far as the future is concerned, it's our R&D pipeline, right? And PN881, the oral IO-17 blocker, is the lead over there. Our vision is really to revolutionize the whole eye and eye space, which is dominated by injectable... Blockbuster antibody drugs. So if you can create an oral IO-23, why can't you create an oral IO-17? And why can't you create an oral IO-4 down the road? But getting back to the IO-17, so 881, we really loved the phase one data that we generated. We shared a little bit of it with you folks. Most likely, we'll share more details at a medical conference next year, maybe in the first half of next year. But the data is, the drug levels we saw in the healthy volunteers gave us all the conviction to move forward with a very comprehensive phase to the study in psoriasis, and we have sketched out the study detail in our corporate tech as well. But the idea would be to then extract a dosic regimen through which we can directly go into a phase three study. The other thing we are going to do is, you know, if your drug is working, then in psoriasis, then the response rates are high, expected to be high. So even studying at the blinded data, you should be able to make a judgment call. And by the way, if your drug is not working, you will definitely be able to tell it's not working, studying at the blinded data, right? So the point is, like, we are not going to wait for the phase to study to be completed. We will just, in the second half of next year, assuming the enrollment is going at a decent pace, make a judgment call on the second indication. So that is something we should be able to share.
Roger Song, Analyst — Jefferies
Got it. So you say, would you be able to share some blinded data, or is it just your decision to move into the next?
Dinesh V. Patel, CEO
Just the decision. Just a teaser.
Roger Song, Analyst — Jefferies
Yeah, got it. And then that decision is indication, which indication is on the top of your mind?
Dinesh V. Patel, CEO
That is largely undecided, but maybe psoriatic arthritis will be a good choice. HS has more uncertainties, and recently it has surprised many companies in an unpleasant way through high placebo rates and, you know, that sort of thing. So it's a bit complex. So maybe we should get more familiar with our drug and its performance before we dive into H.S. That is the current thinking. We may change our mind. And then with regard to the GGG, PN477, we did a single ascending dose study, single dose study in healthy volunteers, and we really liked the data that we saw. I mean, we saw a nice PKPD dose response. We saw clinical activity as well. And based on that, we basically said, and remember I mentioned early on that we are always about differentiation. So then it's like with sub-Q, we got the quote-unquote proof or that evidence of clinical activity that we were looking for, and that was good enough. It served the purpose. We don't see much value at this stage in developing a triple sub-Q on our own when retatutide is already showing great data, heads off to Eli Lilly in a phase three study. Okay. So our focus is on the oral, the oral triple. So that has become the high priority right now. And in a way, what we are doing in obesity is like now it's just a, we are creating a portfolio with oral peptide drugs, the oral triple, the oral dual is maybe six months behind it. And then also we are working on oral amylin, although it's a bit early.
Roger Song, Analyst — Jefferies
Okay, got it. So one comment you have is for the sub-Q, you say rather to the level activity at a much lower dose. And then now you're focused on the oral side. How do we think about the oral potency and exposure level compared to your sub-Q?
Dinesh V. Patel, CEO
Another great question. So, you know, pre-clinically also we made observations that if you do... Equal milligram dosing of, let's say, ratatroutide versus PN477, we were seeing... Observable, better weight loss or higher weight loss with our drug. And in phase one, what we saw now, these are cross-trial comparisons, so one has to take it with a grain of salt, but for data to tide, single dose data is out there. So when we compare it with our data, what we find is that So, whatever effect ratatatide created at a particular dose, our drug will do it at four to five times lower dose. So, then loosely it is translating to maybe higher potency, but I think it will have very positive implications, as you can imagine, right? I mean, now when we go into the oral study, the burden on oral bioavailability or how much material you need, that is going to be lower by four to five times, which would be very significant.
Roger Song, Analyst — Jefferies
Got it. Yeah. So what will be the TPP for your oral? Because your ECOTI is, you know, injectable level efficacy and then the tolerability even better, you know, we can say that. And then for the R17, probably you are targeting the similar level. And then for the oral peptide, oral GGG, the respiratory is a very good activity, and then the tolerability maybe can be improved. So what's your TPP for the oral?
Dinesh V. Patel, CEO
Yeah, in most of these instances, you know, I mean, you're able to do titration to effect, for example. So using obesity as an example, then it will all depend on, you know, how much weight loss is desirable in a particular patient, and then the dosing can be titrated to effect, so to speak. But in broad strokes, with the oral, what we would expect is you have to be in the zip code of the injectables. You don't have to exactly match it. Our advantage is, hey, we are oral, so we can afford to have a little bit of haircut in terms of the efficacy or potency.
Roger Song, Analyst — Jefferies
Got it. So one of the key aspects of the oral is the bioavailability. And then I know you have a discovery platform for the oral peptide developing very potent drug. How about the formulation and the bioavailability, and then what's the bioavailability you have for the oral GGG to ensure the exposure level?
Dinesh V. Patel, CEO
Yeah, I think the first act should be, as much as possible, you should try to design your peptide in such a way that it has inherent bias towards better bioavailability. If you think about it, for icotide, for example, there is no formulation assistance, right? And yet its performance is amazing. So what we strive for is like amazing potency, which, by the way, also translates to very high level of specificity, a big advantage over small molecules, right? And that kind of lowers the burden of bioavailability. But yeah, you can enhance the bioavailability through specific formulations. So, obviously, we are kind of taking advantage of that as well, but it's a balancing act of the core potency, the core biolability of your peptide, and enhancing it a little bit through formulation, and then, of course, you know, fine-tuning the half-life, so once the drug is in the bloodstream, then it hangs around to get the job done.
Roger Song, Analyst — Jefferies
Got it. Okay, just lastly, you had two very successful partnerships. One is very early on, research stage. The other one is near phase three data, and then also mostly the commercial. Now you have two new kids, so to speak. That's right. It's a growing family. Yeah, and then the INI and then the Obesity, you know, admittedly, I think Obesity is probably more involved on the capital side. How do you think about the partnering strategy for your two?
Dinesh V. Patel, CEO
I think it's a fantastic question. In the obesity space, we have no illusions of doing phase three studies on our own. It's really a portfolio that will benefit from a partnership. With the oral IR-17, we are already on our way towards a phase two. With psoriasis, we will take on other indications, but I think at the right junction, maybe before we go into phase three, that could be one inflection point where a partnership could do a wonderful job. And just by doing a partnership, we don't have to give it up. Now we have the financial strength to participate in co-development, clinical co-development, and those sort of things, right? So the idea will be to retain better economics and do deals that will be valued and accepted by the shareholders.
Roger Song, Analyst — Jefferies
By the way, your Takido partnership is the amazing economics for you in the latest.
Dinesh V. Patel, CEO
I jokingly tell people it's like Mimrilo is like, okay, and it's a rare disease drug, as you know. So it's like we have a... Bigger portion of a small pie, and with icotide, it's a much bigger pie, so we may have a smaller portion of a much bigger pie, and then it's up to, the numbers will do the talking.
Roger Song, Analyst — Jefferies
Okay, great. Thank you so much, Dinesh, and thank you, everyone.
Dinesh V. Patel, CEO
Thank you.